Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Mallinckrodt
Moodys
Colorcon
McKesson

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Litigation Details for Salix Pharmaceuticals, Ltd. v. Actavis Laboratories FL, Inc. (D. Del. 2016)

See Plans and Pricing

« Back to Dashboard

Salix Pharmaceuticals, Ltd. v. Actavis Laboratories FL, Inc. (D. Del. 2016)

Docket   Start Trial Date Filed 2016-03-23
Court District Court, D. Delaware Date Terminated 2018-09-17
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ACTAVIS LABORATORIES FL, INC.; ALFA WASSERMANN S.P.A.; ALFASIGMA S.P.A.; CEDARS-SINAI MEDICAL CENTER; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A.R.L.
Patents 6,861,053; 7,045,620; 7,452,857; 7,605,240; 7,612,199; 9,271,968; 9,421,195
Attorneys Alexandra D. Valenti; Brian J. Robinson; Dana Kathryn Severance; Daniel Marcus Attaway; David A. Bilson; Elizabeth J. Holland; J. Anthony Downs; Jeffrey Colin; John C. Phillips , Jr.; Joshua S. Weinger; Linnea P. Cipriano; Mary W. Bourke; Michael E. Furrow; Robert V. Cerwinski; Scott K. Reed; Srikanth K. Reddy; Steven C. Kline; Tiffany Mahmood
Firms Phillips, Goldman, McLaughlin & Hall, P.A.; Womble Bond Dickinson (US) LLP; Womble Carlyle Sandridge & Rice, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Salix Pharmaceuticals, Ltd. v. Actavis Laboratories FL, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Salix Pharmaceuticals, Ltd. v. Actavis Laboratories FL, Inc. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-06-14 17 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,271,968; . (Bourke, Mary) (… 17 September 2018 1:16-cv-00188 830 Patent None District Court, D. Delaware External link to document
2016-03-23 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,861,053; 7,045,620; 7,452,857… 17 September 2018 1:16-cv-00188 830 Patent None District Court, D. Delaware External link to document
2016-12-12 53 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) addition of U.S. Patent No. 9,421,195; . (Bourke… 17 September 2018 1:16-cv-00188 830 Patent None District Court, D. Delaware External link to document
2017-01-13 59 Preliminary Infringement Contentions for U.S. Patent No. 9,421,195 Against Actavis Laboratories FL, Inc.; and… 17 September 2018 1:16-cv-00188 830 Patent None District Court, D. Delaware External link to document
2017-01-27 63 Inc.'s preliminary list of terms in U.S. Patent No. 9,421,195 in need of construction and the [CONFIDENTIAL… 17 September 2018 1:16-cv-00188 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Express Scripts
Harvard Business School
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.